Published in Lancet on November 04, 1978
Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut (1987) 1.57
Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut (1981) 1.23
Prostaglandins, thromboxanes and leukotrienes in clinical medicine. West J Med (1985) 1.02
Phagocytes, toxic oxygen metabolites and inflammatory bowel disease: implications for treatment. Ann R Coll Surg Engl (1990) 0.82
Inflammatory intermediaries in inflammatory bowel disease. Int J Colorectal Dis (1989) 0.82
Mechanism of action of 5-arninosalicylic acid. Mediators Inflamm (1992) 0.79
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 5.34
Effect of an enteric-coated fish-oil preparation on relapses in Crohn's disease. N Engl J Med (1996) 3.47
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut (2004) 3.01
Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut (2004) 2.29
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther (1999) 2.26
Detection of malabsorption of low doses of carbohydrate: accuracy of various breath H2 criteria. Gastroenterology (1993) 2.15
Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas. Lancet (1981) 2.02
Expanded indications for ultrasound-guided thrombin injection of pseudoaneurysms. J Vasc Surg (2000) 1.77
Expression of the antiproliferative gene TIS21 at the onset of neurogenesis identifies single neuroepithelial cells that switch from proliferative to neuron-generating division. Proc Natl Acad Sci U S A (1999) 1.73
Enhanced mucosal interleukin-6 and -8 in Helicobacter pylori-positive dyspeptic patients. Am J Gastroenterol (1994) 1.69
Incidence of inflammatory bowel disease in Italy: a nationwide population-based study. Gruppo Italiano per lo Studio del Colon e del Retto (GISC) Int J Epidemiol (1996) 1.65
Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am J Pathol (1999) 1.62
Interaction of probiotic Lactobacillus and Bifidobacterium strains with human intestinal epithelial cells: adhesion properties, competition against enteropathogens and modulation of IL-8 production. Int J Food Microbiol (2008) 1.61
Steroid treatment in active Crohn's disease: a comparison between two regimens of different duration. Aliment Pharmacol Ther (1994) 1.59
Endoscopic markers in adult coeliac disease. Dig Liver Dis (2002) 1.58
Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration. Kidney Int (2001) 1.51
Controlled study using wireless capsule endoscopy for the evaluation of the small intestine in chronic refractory pouchitis. Aliment Pharmacol Ther (2007) 1.49
Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study. Dig Liver Dis (2007) 1.43
Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment. Am J Gastroenterol (2001) 1.43
Review article: the management of refractory Crohn's disease. Aliment Pharmacol Ther (2002) 1.41
Probiotics in inflammatory bowel disease: new insight to pathogenesis or a possible therapeutic alternative? Gastroenterology (1999) 1.40
A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology (1986) 1.37
Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut (2006) 1.36
Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther (2006) 1.33
Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci (1999) 1.29
Polyunsaturated fatty acids and inflammatory bowel disease. Am J Clin Nutr (2000) 1.27
Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther (1999) 1.24
[Epidemiological study on intestinal inflammatory diseases in the Province of Bologna]. G Clin Med (1977) 1.21
Relapsing ulcerative colitis after spinal cord stimulation: a case of intestinal neurogenic inflammation? Gastroenterology (1999) 1.16
Rectal dialysate and fecal concentrations of neutrophil gelatinase-associated lipocalin, interleukin-8, and tumor necrosis factor-alpha in ulcerative colitis. Am J Gastroenterol (1999) 1.16
Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion. Gut (1985) 1.15
Effect of probiotic strains on interleukin 8 production by HT29/19A cells. Am J Gastroenterol (2002) 1.15
Genome search in celiac disease. Am J Hum Genet (1998) 1.14
Dietary habits as risk factors for inflammatory bowel disease. Eur J Gastroenterol Hepatol (1995) 1.12
Prostaglandins, indomethacin, and ulcerative colitis. Gastroenterology (1980) 1.11
Local injection of Infliximab for the treatment of perianal Crohn's disease. Dis Colon Rectum (2005) 1.09
Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther (2002) 1.07
Mucosal concentrations of interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in pelvic ileal pouches. Dig Dis Sci (1994) 1.05
Anti-Saccharomyces cerevisiae antibodies (ASCA) and autoimmune liver diseases. Clin Exp Immunol (2003) 1.04
Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther (2002) 1.04
Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. Aliment Pharmacol Ther (2009) 1.03
Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol (1998) 1.03
Rectal cell proliferation and colon cancer risk in ulcerative colitis. Cancer Res (1990) 1.02
Changes in splanchnic hemodynamics in inflammatory bowel disease. Non-invasive assessment by Doppler ultrasound flowmetry. Scand J Gastroenterol (1992) 1.01
Epidemiological characteristics of inflammatory bowel disease in Bologna, Italy--incidence and risk factors. Digestion (1993) 1.00
Effects of chronic heroin abuse on bone and mineral metabolism. Acta Endocrinol (Copenh) (1993) 0.99
Different patterns of intestinal transit time and anorectal motility in painful and painless chronic constipation. Gut (1984) 0.98
p-ANCA and development of pouchitis in ulcerative colitis patients after proctocolectomy and ileoanal pouch anastomosis. Lancet (1994) 0.98
Clinical course of ulcerative colitis in Italy. Digestion (1980) 0.97
Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment Pharmacol Ther (2008) 0.97
Probiotics in infective diarrhoea and inflammatory bowel diseases. J Gastroenterol Hepatol (2000) 0.97
Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis (2001) 0.96
A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. Digestion (1984) 0.96
Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn's disease: a meta-analysis. Am J Gastroenterol (1994) 0.95
Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci (1991) 0.95
Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003. Int J Colorectal Dis (2001) 0.94
Importance of laboratory parameters in the evaluation of Crohn's disease activity. J Clin Gastroenterol (1986) 0.93
CT-guided percutaneous pelvic abscess drainage in Crohn's disease. Tech Coloproctol (2006) 0.93
Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut (1991) 0.92
Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis. Dig Dis Sci (1992) 0.91
Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther (2001) 0.91
Combined carriership of TLR9-1237C and CD14-260T alleles enhances the risk of developing chronic relapsing pouchitis. World J Gastroenterol (2005) 0.91
Review--antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach. Eur Rev Med Pharmacol Sci (2000) 0.91
Specificity of leucocyte migration inhibition test in coeliac disease. A reassessment using different gluten subfractions. Clin Exp Immunol (1985) 0.90
New insights into the brain involvement in patients with Crohn's disease: a voxel-based morphometry study. Neurogastroenterol Motil (2012) 0.90
Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Dig Dis Sci (1992) 0.90
Potential role of the cannabinoid receptor CB in the pathogenesis of erosive and non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther (2010) 0.89
Measurements of the jejunal unstirred layer in normal subjects and patients with celiac disease. Am J Physiol (1996) 0.88
Oral budesonide in the treatment of chronic refractory pouchitis. Aliment Pharmacol Ther (2007) 0.88
5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol (1988) 0.88
Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther (1997) 0.87